Probiotics

Probiotics may help with some digestive problems, but “probiotic” is not a single intervention. A product containing Lactobacillus rhamnosus GG is not interchangeable with one containing Bifidobacterium animalis BB-12, Saccharomyces boulardii, or a multi-strain blend. The most defensible answer is that certain tested preparations may help in particular situations, especially antibiotic-associated diarrhea, while broad claims about gut health or IBS remain unproven.

A large review of 82 randomized trials found that probiotics were associated with a lower risk of antibiotic-associated diarrhea. Its pooled estimate suggested a relative risk of 0.58, or about a 42% relative reduction, but the studies often failed to document the exact strains. That makes the result useful for the category, but weak evidence for choosing any particular product.[2][10]

A strain is a distinct lineage within a microorganism species. Research may identify it with a code or designation, such as LGG, BB-12, or I-745. Different strains can behave differently in the intestine, produce different compounds, and interact differently with the host. Even a promising result for one Lactobacillus strain does not establish a benefit for another Lactobacillus strain.

This is why product labels matter. A qualitative review suggested that Saccharomyces boulardii I-745 may perform well for antibiotic-associated diarrhea, while a pediatric trial found benefit with Lactobacillus rhamnosus GG. Those findings are signals about particular preparations, not proof of a universal winner. The broader literature also includes many studies that report only a genus or species, making precise comparison difficult.[10][5][1][2]

The clearest human question is whether probiotics can prevent diarrhea that occurs during or after antibiotics. The broad meta-analysis supports a possible benefit, but the effect probably depends on the antibiotic, the person’s baseline risk, and the preparation used. A 2019 randomized pilot study directly enrolled 36 adults taking amoxicillin-clavulanate. Its six-strain Lactobacillus-and-Bifidobacterium product delayed the first diarrheal episode by roughly four to five days compared with placebo, but it did not clearly reduce the overall proportion developing diarrhea or improve quality of life.

The evidence is not uniformly positive. In a newer randomized trial, healthy children taking relatively low-risk outpatient antibiotic courses received either yogurt with BB-12 or control yogurt. Diarrhea occurred in 2% of each group, and adverse events were similar. This was not an adult study, but it illustrates an important boundary: when the antibiotic causes little microbiome disruption and the baseline diarrhea risk is very low, there may be little room for a probiotic to show benefit. A pediatric evidence synthesis also found a protective association, but rated the evidence moderate and noted substantial variation among strains and study methods.[2]

For adult IBS, the supplied evidence does not justify treating probiotics as a reliable, one-size-fits-all therapy. A randomized trial of 350 generally healthy people with self-reported bloating or indigestion found that a six-week multi-species synbiotic improved gastrointestinal quality of life, bloating, gas, abdominal discomfort, and bowel habits. That is encouraging for a specific product and symptom group, but it does not prove treatment of diagnosed IBS.

The product was a synbiotic, meaning it combined microorganisms with another ingredient intended to support them, and it also contained pomegranate extract. Therefore, the result cannot isolate the effect of the probiotic strains. Pediatric reviews of functional abdominal pain disorders found modest or strain-specific signals, but their participants were children rather than adults. One 2026 network meta-analysis registered its protocol and included 21 randomized trials, yet most comparisons still had low-to-moderate certainty, and several strain-level results were imprecise.[6][9]

Small trials in otherwise healthy people are generally reassuring. The adult antibiotic-associated diarrhea pilot reported no adverse effects in either group, and pediatric prevention trials mainly reported occasional symptoms such as gas, bloating, nausea, or abdominal discomfort rather than serious probiotic-attributable events. These studies were not large enough to rule out rare problems, and safety findings from healthy participants may not apply to people who are severely ill or immunocompromised.

The National Center for Complementary and Integrative Health notes that severe or fatal probiotic-associated infections have been reported in premature infants, and serious events have also been described in severely debilitated or immunocompromised children. That evidence does not quantify risk for adults, but it supports caution in people with major medical vulnerabilities. In the United States, many probiotics are marketed as foods or dietary supplements rather than approved drugs, so a label’s broad health claim is not the same as product-level clinical proof. For a more evidence-based comparison, look for the complete strain designation, the exact condition studied, and a trial of the same combination rather than relying only on a large microorganism count or the phrase “live cultures.”[4]